These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Research and development productivity map: visualization of industry status. Shimura H; Masuda S; Kimura H J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433 [TBL] [Abstract][Full Text] [Related]
23. Massachusetts: Mass effect. Savage N Nature; 2016 Sep; 537(7618):S18-9. PubMed ID: 27580137 [No Abstract] [Full Text] [Related]
24. Innovative drug R&D in China. Qi J; Wang Q; Yu Z; Chen X; Wang F Nat Rev Drug Discov; 2011 May; 10(5):333-4. PubMed ID: 21532556 [No Abstract] [Full Text] [Related]
25. Market watch: Trends in pharmaceutical company R&D spending: 2005-2015. Dixit R; David FS Nat Rev Drug Discov; 2017 Jun; 16(6):376. PubMed ID: 28496145 [No Abstract] [Full Text] [Related]
26. Prescription for an ailing pharmaceutical industry. Demain AL Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826 [No Abstract] [Full Text] [Related]
27. Mike Varney. Varney M; Mullard A Nat Rev Drug Discov; 2015 Mar; 14(3):158-9. PubMed ID: 25677359 [No Abstract] [Full Text] [Related]
28. Combating the cons of consolidation. Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592 [No Abstract] [Full Text] [Related]
29. The pharmaceutical industry and research in 2002 and beyond. Dutta AS; Garner A Drug News Perspect; 2003 Dec; 16(10):637-48. PubMed ID: 14747843 [TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical sciences in 2020. Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959 [No Abstract] [Full Text] [Related]
32. Does size matter in R&D productivity? If not, what does? Ringel M; Tollman P; Hersch G; Schulze U Nat Rev Drug Discov; 2013 Dec; 12(12):901-2. PubMed ID: 24136396 [No Abstract] [Full Text] [Related]
33. An audience with … Wolfgang Plischke. Plischke W; Mullard A Nat Rev Drug Discov; 2014 Apr; 13(4):252. PubMed ID: 24687059 [No Abstract] [Full Text] [Related]
34. New drug approval success rate in Europe in 2009. Eichler HG; Aronsson B; Abadie E; Salmonson T Nat Rev Drug Discov; 2010 May; 9(5):355-6. PubMed ID: 20431561 [No Abstract] [Full Text] [Related]
35. What drives operational performance in clinical R&D? Ringel M; Martin L; Hawkins C; Panier V; Denslow M; Buck L; Schulze U Nat Rev Drug Discov; 2016 Mar; 15(3):155-6. PubMed ID: 26846158 [No Abstract] [Full Text] [Related]
36. R&D productivity: on the comeback trail. Schulze U; Baedeker M; Chen YT; Greber D Nat Rev Drug Discov; 2014 May; 13(5):331-2. PubMed ID: 24751818 [No Abstract] [Full Text] [Related]
37. Drug development risk and the cost of capital. Baras AI; Baras AS; Schulman KA Nat Rev Drug Discov; 2012 Apr; 11(5):347-8. PubMed ID: 22498751 [No Abstract] [Full Text] [Related]
38. How to revive breakthrough innovation in the pharmaceutical industry. Munos BH; Chin WW Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677 [TBL] [Abstract][Full Text] [Related]